Moreover, emerging biomarkers like VILIP-1 could potentially substitute for t-tau and p-tau as markers of AD brain pathology in studies where tau-related biomarkers may be directly affected (e.g., drug trials of anti-tau antibodies), similarly for Abeta. This evidence concerns the gene MAPT and Alzheimer disease.